HM
HealthCor Management Portfolio holdings
AUM
$109M
This Quarter Return
+12.56%
1 Year Return
+11.46%
3 Year Return
+50.01%
5 Year Return
+144.68%
10 Year Return
–
AUM
$2.18B
AUM Growth
+$2.18B
(+25%)
Cap. Flow
+$297M
Cap. Flow
% of AUM
13.64%
Top 10 Holdings %
Top 10 Hldgs %
65.42%
Holding
52
New
13
Increased
11
Reduced
11
Closed
14
Top Buys
| 1 |
BIVV
Bioverativ Inc. Common Stock
BIVV
|
$272M |
| 2 |
Edwards Lifesciences
EW
|
$118M |
| 3 |
Vertex Pharmaceuticals
VRTX
|
$112M |
| 4 |
AET
Aetna Inc
AET
|
$93.9M |
| 5 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$83.5M |
Top Sells
| 1 |
Quest Diagnostics
DGX
|
$103M |
| 2 |
QGENF
QIAGEN NV
QGENF
|
$79.9M |
| 3 |
Danaher
DHR
|
$75.8M |
| 4 |
Incyte
INCY
|
$74.3M |
| 5 |
Zimmer Biomet
ZBH
|
$69.6M |
Sector Composition
| 1 | Healthcare | 87.1% |
| 2 | Financials | 9.22% |
| 3 | Materials | 1.56% |
| 4 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
BIVV
1
DELISTED
Bioverativ Inc. Common Stock
BIVV
| $272M | 12.49% | +5,000,000 | New | +$272M |
|
|
AET
2
DELISTED
Aetna Inc
AET
| $201M | 9.22% | 1,575,000 +735,970 | +88% | +$93.9M |
|
|
CELG
3
DELISTED
Celgene Corp
CELG
| $174M | 7.99% | 1,400,000 -100,000 | -7% | -$12.4M |
|
4
Labcorp
LH
$23.1B
| $147M | 6.75% | 1,025,000 -125,000 | -11% | -$17.9M |
|
|
5
Edwards Lifesciences
EW
$47.8B
| $118M | 5.39% | +1,250,000 | New | +$118M |
|
|
ALXN
6
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $115M | 5.28% | 950,000 +688,860 | +264% | +$83.5M |
|
7
Intuitive Surgical
ISRG
$170B
| $115M | 5.27% | 150,000 -25,000 | -14% | -$19.2M |
|
|
8
Vertex Pharmaceuticals
VRTX
$100B
| $112M | 5.14% | +1,025,000 | New | +$112M |
|
9
Merck
MRK
$210B
| $93.7M | 4.3% | 1,475,000 +907,530 | +160% | +$57.7M |
|
|
SYNH
10
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
| $77.9M | 3.58% | 1,700,000 +576,080 | +51% | +$26.4M |
|
11
Haemonetics
HAE
$2.63B
| $64.9M | 2.98% | 1,600,000 +450,000 | +39% | +$18.3M |
|
12
Align Technology
ALGN
$10.3B
| $60.2M | 2.76% | 525,000 +422,737 | +413% | +$48.5M |
|
13
Neurocrine Biosciences
NBIX
$13.8B
| $53M | 2.43% | 1,225,000 +236,100 | +24% | +$10.2M |
|
14
Qiagen
QGEN
$10.1B
| $50.7M | 2.33% | +1,750,000 | New | +$50.7M |
|
15
Pacira BioSciences
PCRX
$1.2B
| $50.2M | 2.3% | 1,100,000 -475,000 | -30% | -$21.7M |
|
16
Sarepta Therapeutics
SRPT
$1.78B
| $45.9M | 2.1% | +1,550,000 | New | +$45.9M |
|
17
Zoetis
ZTS
$69.3B
| $37.4M | 1.71% | +700,000 | New | +$37.4M |
|
18
Baxter International
BAX
$12.7B
| $35M | 1.61% | 675,000 +381,350 | +130% | +$19.8M |
|
|
MON
19
DELISTED
Monsanto Co
MON
| $34M | 1.56% | 300,000 +175,000 | +140% | +$19.8M |
|
20
HCA Healthcare
HCA
$94.5B
| $28.9M | 1.33% | 325,000 +167,740 | +107% | +$14.9M |
|
|
ALR
21
DELISTED
Alere Inc
ALR
| $28.8M | 1.32% | +725,000 | New | +$28.8M |
|
22
UnitedHealth
UNH
$281B
| $28.7M | 1.32% | 175,000 -232,580 | -57% | -$38.1M |
|
|
CVRS
23
DELISTED
CORINDUS VASCULAR ROBOTICS, INC
CVRS
| $26.2M | 1.2% | 19,981,655 | – | – |
|
24
Humana
HUM
$36.5B
| $25.8M | 1.18% | +125,000 | New | +$25.8M |
|
25
Bristol-Myers Squibb
BMY
$96B
| $24.5M | 1.12% | +450,000 | New | +$24.5M |
|